HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis
Jiahui Si, Yuanyuan Ma, Chao Lv, Yang Hong, Hongyu Tan, Yue Yang
Abstract
. RNA precipitation assays, western blotting, luciferase assays, and rescue experiments demonstrated that HIF1A-AS2 sponged microRNA-146b-5p (miR-146b-5p), promoting interleukin-6 (IL-6) expression, activating the IL-6/STAT3 pathway, and leading to LUAD progression. miR-146b-5p and IL-6 levels were correlated with the prognosis of LUAD patients. Our results indicated that HIF1A-AS2 functions as an oncogenic factor in adenocarcinoma cells by targeting the miR-146b-5p/IL-6/STAT3 axis and may be a prognostic indicator of survival. Moreover, it can be a potential therapeutic target to enhance the efficacy of osimertinib in LUAD patients.
Topics & Concepts
OsimertinibAdenocarcinomaMedicineSTAT3LungHIF1AInternal medicineCancer researchOncologyBiologySignal transductionCell biologyCancerAngiogenesisROS1Cancer-related molecular mechanisms researchRNA modifications and cancerLung Cancer Treatments and Mutations